In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alaunos Therapeutics, Inc.

www.alaunos.com

Latest From Alaunos Therapeutics, Inc.

Dissecting Piramal’s Damages Award In Sensipar Case

A legal expert details how Piramal Healthcare could turn the tables and secure damages in the litigation pertaining to its generic version of Amgen's Sensipar, a case which saw multiple at-risk launches.

Legal Issues Generic Drugs

Positive Medtech Revenues Into H2, But M&A And IPOs May Wait

EY’s John Babitt provided a mid-year 2022 update on medtech investment trends, and the outlook for the industry going into 2023 in this commentary for In Vivo.

Market Intelligence Medical Device

Texas To Tokyo: Japan Darvias Approval Marks End Of Long Development Road

Solasia's arsenical drug darinaparsin has received its global-first approval in Japan, for PTCL, in a landmark for the Texan chemist who discovered it back in the 70s and paving the way for wider indications and Asian markets.

Japan Approvals

Stock Watch: Pharma Castoffs Sink Without A Trace … Eventually

When a small biotech company acquires a failed drug from big pharma and plans to repeat the clinical studies expecting a positive result, is that not a definition of insanity?

Stock Watch Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Other Names / Subsidiaries
    • Eden Biocell, Ltd, Ziopharm Oncology, Inc.
UsernamePublicRestriction

Register